– IBIO-201 Demonstrates Ability to Elicit anti-SARS-CoV-2 Immune Response in Preclinical Studies –
NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) — iBio, Inc.
(NYSE AMERICAN:IBIO) (iBio or the Company)…
Read More

Leave a Reply